About 403 results

ALLMedicine™ Acute Bronchospasm Center

Research & Reviews  29 results

Ammonia Toxicity Treatment & Management

Apr 11th, 2022 - Approach Considerations Management of toxic exposure to ammonia is largely supportive. Decontaminate the patient (if that was not done at the site of exposure) and support airway, breathing, and circulation (ABCs) as necessary. Provide warmed humi...

Unusual Presentation of Atrial Myxoma: A Case Report and Review of the Literature.
The American Journal of Case Reports; Jaravaza DR, Lalla U et. al.

May 4th, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Computed Tomography Scan Evidence of Bronchospasm and Its Resolution During Computed To...
A&A Practice; Munaf M, Gadhinglajkar S et. al.

Mar 9th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Theophylline Level

Feb 10th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Tissue traction microscopy to quantify muscle contraction within precision-cut lung sli...
American Journal of Physiology. Lung Cellular and Molecul... Ram-Mohan S, Bai Y et. al.

Nov 28th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

see more →

Drugs  105 results see all →

Clinicaltrials.gov  3 results

Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial

Dec 22nd, 2016 - Despite few scientific evidence that could support the use of ketamine in adult patients undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely employed in this setting. The aim of this study is therefore assess m...

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Apr 8th, 2016 - This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospa...

Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD

Jun 23rd, 2011 - Beta-blockers are indicated in the management of numerous medical conditions including angina pectoris, myocardial infarction, hypertension, congestive heart failure, cardiac arrhythmia, systemic hypertension, as well as to reduce complications in...

see more →

News  24 results

FDA OKs First-in-Class Biologic for Severe Asthma

Dec 20th, 2021 - The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced Friday. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an add-on maintenanc...

FDA approves benralizumab autoinjector for eosinophilic asthma
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA Expands Indication for Trelegy Ellipta in COPD

Apr 24th, 2018 - The US Food and Drug Administration (FDA) has approved an expanded indication for GlaxoSmithKline's single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include a broader population of chronic obstructive ...

FDA Expands Indication for Trelegy Ellipta in COPD

Apr 24th, 2018 - The US Food and Drug Administration (FDA) has approved an expanded indication for GlaxoSmithKline's single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include a broader population of chronic obstructive ...

FDA approves triple-therapy inhaler for COPD
Pulmonary Health Hub; Lucas Franki

Sep 19th, 2017 - The Food and Drug Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple-therapy inhaler for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients, according to a press release.

see more →